Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Metastatic Castration-Resistant Prostate Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 1,200 (planned)
- Started
- Nov 17, 2016
- Main results expected
- Oct 22, 2027
- Fully finished
- Jul 24, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants With a Decrease of ≥50% in Prostatic Specific Antigen (PSA)
Measured over: From Baseline Measured Every 3 Weeks Until Radiographic Progression Estimated to be Approximately 2 Years
Number of Participants with Adverse Events (AEs)
Measured over: Assessed Every 3 Weeks Over the Duration of the Study Which is Estimated to be Approximately 2 Years
Number of Participants Discontinuing Study Drug Due to AEs
Measured over: Assessed Every 3 Weeks Over the Duration of the Study Which is Estimated to be Approximately 2 Years
Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR)
Measured over: Assessed Over the Duration of the Study Which is Estimated to be Approximately 2 Years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT02861573 · record last updated 2026-07-13 · checked 2026-11-09 15:47 UTC